
Grand Prize awarded from among 224 participating companies, including 48 overseas companies
CFS Open Innovation Pitch 2024 is one of the largest open innovation events in Japan, with 224 startups entered, including 48 from abroad.
Jericle made a pitch titled "Transforming Medicine, Industry, and Agriculture with Gel" about the applicability of its technology, its strategy and achievements, and its vision for the future. Gericle received the highest evaluation out of 224 participating companies, including 48 from overseas, and was awarded the Grand Prize and a cash prize of 2 million yen, based on its high technological capabilities, contribution to society, track record, and combination with other technologies.

The awards ceremony held on July 26 was broadcast live on YouTube. A digest of the ceremony can be viewed below.
Video clips of the final judging (open pitch judging) held on July 12 can be viewed in the archive below.
About Jericle, Inc.
Gericle is a biotech startup from the University of Tokyo, founded in 2018 with the goal of revolutionizing medicine with Tetragel, the world's only homogeneous gel. Using Tetragel technology, we will create various medical products such as hemostatic agents, anti-adhesive materials, and ophthalmic surgical aids. Winner of the ICC Summit KYOTO 2021 Real Tech Catapult. University Venture Award 2023 University Venture Award Special Prize. Selected for Berkeley SkyDeck, the world's top accelerator.
Company Profile of Jericle, Inc.
| name of company | Gellycle Co. |
| Establishment | August 1, 2018 |
| Location | 2F Sakae Building, 3-38-10 Hongo, Bunkyo-ku, Tokyo |
| representative | Kosuke Masui |
| Business Overview | Research and development of medical products using Tetragel |
| uniform resouce locator | https://gellycle.com/ |









